FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent merger with Echo Therapeutics, Inc., Sontra Medical Corporation , a dual platform-enabled transdermal specialty therapeutics and diagnostics company, today announced that it has changed its corporate name to Echo Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October 8, 2007, the Company’s OTC Bulletin Board ticker symbol will change to “ECTE” and its corporate website address will become www.echotx.com.
“Our new name better reflects our expanded strategic focus on building a broad pipeline of advanced topical formulations of FDA-approved specialty pharmaceutical products and next generation needle-free transdermal diagnostics,” said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.
About Echo Therapeutics
Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical formulations of FDA-approved products and a suite of needle-free transdermal diagnostics. Echo is developing a next generation, needle-free Continuous Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care and hospital critical care markets. Echo’s next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform. Echo is also developing a broad portfolio of advanced topical formulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead Azone TS- based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.
SonoPrep is a registered trademark of Echo Therapeutics, Inc.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and SonoPrep platform technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and a SonoPrep-based continuous transdermal glucose monitor system for the diabetes and hospital critical care markets; the availability of substantial additional equity capital to support our robust research, development and product commercialization activities; and the success of our AzoneTS and SonoPrep business, research, development, and regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward-looking statements.
www.echotx.compmooney@echotx.com
CONTACT: Patrick T. Mooney, M.D., CEO of Echo Therapeutics, Inc.,
+1-508-530-0329, pmooney@echotx.com
Web site: http://www.sontra.com/
http://www.echotx.com/
